Download:
pdf |
pdfForm approved
OMB Control No. 0920-1238
Expiration Date XX/XX/XXXX
The EDN Tuberculosis Follow-Up Worksheet for Newly-Arrived Persons with Overseas Tuberculosis Classifications
A. Demographic
A1. Name (Last, First, Middle):
A6. Sex:
A5. Age:
A2. Alien #:
A3. Visa type:
A4. Initial U.S. entry date:
A7. DOB:
A8. TB Class Based on Technical Instructions for Panel Physicians:
___/___/______
A9. Country of examination:
A10. Country of birth:
A11a. Name in care of:
A12a. Sponsor agency name:
A11b. Phone number:
A12b. Phone number:
A11c. Address:
A12c. Address:
B. Jurisdictional Information
B1. Arrival jurisdiction:
B2. Current jurisdiction:
C. U.S. Evaluation
C1. Date of first U.S. test or provider/clinic visit:
_____/_____/________
Mantoux Tuberculin Skin Test (TST) in U.S.
No
Yes
C3a. Was IGRA performed in the U.S.?
C2a. Was a TST administered in the U.S.?
Yes
Interferon-Gamma Release Assay (IGRA) in U.S.
Unknown
If YES, C3b. Date collected:
If YES, C2b. TST placement date: ____/_____/__________
No
____/____/_____
_______ IUs/Spots
T-SPOT
QuantiFERON®
_____________
Unknown
Other, specify: __________________
C2d. TST interpretation:
Positive
C3d. Result:
C2e. History of Previous Positive TST:
No
Invalid
Unknown
Yes
Unknown
C4. Pre-immigration CXR available?
No
Negative
Unknown
Indeterminate,
Borderline, or
Equivocal
C3e. History of previous positive IGRA:
U.S Review of Pre-Immigration CXR
Yes
Positive
Negative
Unknown
Yes
Date unknown
C3c. IGRA brand:
Placement date uknown
C2c. TST mm:
Unknown
No
Unknown
U.S. Domestic CXR
C6a. U.S. domestic CXR done?
Yes
No
Unknown
If YES, C6b. Date of U.S. CXR: ____/____/_______
Comparison
C8. U.S. domestic
CXR comparison to
pre-immigration CXR:
Stable
Worsening
C5. U.S. interpretation of pre-immigration CXR:
C7. Interpretation of U.S. CXR:
Normal (Negative for TB)
Normal (Negative for TB)
Abnormal
Abnormal
Suggestive of TB
Suggestive of TB
Non-TB Condition
Non-TB Condition
Poor Quality/Not Interpretable
Poor Quality/Not Interpretable
Unknown
Unknown
Improving
Unknown
Public reporting burden of this collection of information is estimated to average 30 minutes per individual, including the time
for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and
reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a
collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden
estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR
Information Collection Review Office, 1600 Clifton Road NE, MS D¬74, Atlanta, Georgia 30333; ATTN: PRA (0920-1238).
The EDN Tuberculosis Follow-Up Worksheet for Newly-Arrived Persons with Overseas Tuberculosis Classifications
Alien #
U.S. Review of Pre-Immigration Treatment
C9a. Completed treatment pre-immigration?
Yes
C9f. Standard TB treatment regimen was administered?
No
Standard TB treatment
Unknown
If YES, C9b.
Treated for TB disease
Unable to verify
Treated for LTBI
C10a. Arrived to the U.S. on treatment?
Treated, but unknown if TB disease or LTBI
Yes
If Treated for TB disease,
Treatment completed after panel physician diagnosis (DS 3030)
If YES, C10b.
At DGMQ-designated DOT site
Start date unknown
C9d. Treatment end date: ___/___/____
End date unknown
Yes
Treatment duration too short
Incorrect treatment regimen
Treatment documented on overseas medical history form (DS 3026)
Inadequate information provided
Documented on DS forms & patient reported at panel physician
examination
Lack of adequate diagnostics
Unknown DOT/adherence status
After U.S. arrival only, patient verbally reported
treatment completion
Unknown
2
3
No
If YES, C11b. Select all that apply:
C9e. Report of treatment administered prior to panel physician
examination:
C12. U.S. Microscopy/Bacteriology*
Date Collected
Undocumented/unverified treatment
Other, specify: ________________________
Sputa collected in U.S.?
Sputum Culture
Positive
Negative
Not Done
Unknown
___/___/_____
___/___/_____
Positive
Negative
Not Done
Unknown
Positive
Negative
Not Done
No *Covers all results regardless of sputa collection method.
Yes
AFB Smear
___/___/_____
Start date unknown
C11a: Pre-Immigration treatment concerns?
Other, specify:________________________________
C9c. Treatment start date: ___/___/____
Treated for LTBI
Treated for TB disease
C10c. Start date: ___/___/____
At non-DGMQ-designated DOT site
1
No
Unknown
Treatment completed prior to panel physician examination
#
Non-standard TB treatment
Unknown
Drug Susceptibility Testing
MDR-TB
Mono-RIF
Negative
Mono-INH
Other DR
Not Done
Unknown
No DR
Not Done
NTM
MTB Complex
MDR-TB
Mono-RIF
Contaminated
Negative
Mono-INH
Other DR
Not Done
Unknown
No DR
Not Done
NTM
MTB Complex
MDR-TB
Mono-RIF
Contaminated
Negative
Mono-INH
Other DR
Not Done
Unknown
No DR
Not Done
NTM
MTB Complex
Contaminated
D. Evaluation Disposition in U.S.
D1a. Evaluation disposition date in U.S.: ___/____/______
D1b. State/jurisdiction of evaluation disposition in U.S.: ______________
D2a. Evaluation disposition in U.S.:
Did not initate evaluation
Completed evaluation
Initiated Evaluation / Not completed
D2b. If evaluation was completed,
was treatment recommended?
D2c. If evaluation was NOT completed, why not? Select all that apply.
Yes
LTBI
Active TB
D3. Diagnosis
No
Lost to Follow-Up
Moved within U.S., transferred to:_______________________
State/jurisdiction
Moved outside U.S.
Refused Evaluation
Died
Unknown
Other, specify: _______________
Not Located
Class 0 - No TB exposure, not infected or Class 1 - TB exposure, no evidence of infection
Class 2 - TB infection, no disease
Class 4 - TB, inactive disease
Class 3 - TB, TB disease
Pulmonary
Culture-confirmed
Extra-pulmonary
Yes
Both sites
No
The EDN Tuberculosis Follow-Up Worksheet for Newly-Arrived Persons with Overseas Tuberculosis Classifications
Alien #
D4. If diagnosed with TB disease:
State Case Number:
RVCT # unknown*
RVCT Reported*
TBLISS # unknown*
TBLISS Reported*
Year
_____
_______________________________
State
RVCT # / TBLISS #
City/County Case Number:
Year
_____
_______________________________
State
RVCT # / TBLISS #
*Note: Either the RVCT or TBLISS number may be reported.
E. U.S. Treatment for TB Disease or TB Infection
E1a. U.S. treatment initiated:
Yes
No
Unknown
E1b. If NO, specify the reason. Select all that apply:
Patient declined against medical advice
Lost to follow-up
Died
Moved outside the U.S.
Currently on treatment
Treatment not offered based on
local clinic guidelines
Contraindication for treatment
E1c. If YES:
Treated for TB disease
E2. Treatment start date: ___/____/_______
Moved within U.S., transferred to:______________
State/jurisdiction
Prior treatment completed (year: _________)
Unknown
Other, specify:_____________________________
Treated for LTBI
E3. State/jurisdiction of treatment in U.S.: ______________
E4. Specify initial LTBI regimen:
Isoniazid (9 months; 9H)
Isoniazid (6 months; 6H)
Isoniazid/Rifapentine (3 months; 3HP)
Isoniazid/Rifampin (INH+RIF; 4 months)
Rifampin (4 months; 4R)
Isoniazid/Rifampin/Ethambutol/Pyrazinamide (RIPE; 2 months; suspected TB disease)
Unknown
Other, specify: _________________________________________________________
E5a. U.S. treatment completion status and dates:
Completed _____/_____/_________
Treatment ongoing
Treatment discontinued/stopped _____/_____/________
Unknown
*Completed refers to finished treatment, Treatment ongoing refers to treatment that is initiated but not yet completed. Treatment discontinued/stopped refers to
initiated treatment that is not completed.
If treatment discontinued/stopped, E5b. Specify the reason. Select all that apply:
Patient declined against medical advice
Died
Dying (treatment stopped because
of imminent death, regardless of cause
of death)
Provider decision
F. Evaluation Site Information
Provider’s Name:
Lost to follow-up
Moved outside the U.S.
Moved within U.S., transferred to:________
Unknown
Other, specify: ______________________
Adverse effect
Not TB disease
Pregnancy [For patient
diagnosed with LTBI]
Developed TB [For
patient diagnosed with
LTBI]
G. Treatment Site Information
Provider’s Name:
Clinic Name:
Clinic Name:
Telephone Number:
Telephone Number:
Same as evaluation site information
H. Comments
State/ jurisdiction
File Type | application/pdf |
File Title | WorksheetGen |
File Modified | 2021-03-04 |
File Created | 2013-08-06 |